Healthcare giant Johnson & Johnson is looking to generate as much as $100 billion in 2022 after more than doubling its earnings in the last quarter of the previous year, the firm announced in a filing.

  • J&J expects reported sales to range from $98.9 billion to $100.4 billion, up by as much as 7.0% from the previous year. This includes up to $3.5 billion it expects to raise from its COVID-19 vaccine and up to $96.9 billion from other streams.
  • The company’s fourth-quarter sales grew by 10.4% to $24.804 billion from $22.475 billion the previous year, bringing the full-year figure up 13.6% to $93.775 billion from $82.584 billion.
  • The pharmaceutical business accounted for the most significant share during the quarter, followed by medical devices and consumer health. The same pattern was recorded for the full-year period.
  • Net earnings for the fourth quarter soared by 172.5% to $4.736 billion, equivalent to diluted earnings per share of $1.77. This brought the full-year net earnings up 41.9% to $20.878 billion and diluted earnings per share at $7.81.

Chief Executive Officer Joaquin Duato welcomed the results, saying the company is “well-positioned” for success this year and beyond. J&J is down 1.61%.